Abstract
Transsphenoidal surgery (TSS) is a well recognised treatment for secreting pituitary adenomas, however a very wide variation of clinical outcomes and recurrence rates has been reported, depending on the different criteria used to define the cure. We reported the clinical outcome of a large series of patients operated on for a secreting pituitary adenoma according to the most recent stringent criteria of biochemical remission nowadays accepted. One hundred and twenty-five consecutive patients with a secreting pituitary adenoma (42 PRL-, 67 GH- and 16 ACTH-secreting adenomas) who were operated on by the two same neurosurgeons were considered for the study. Biochemical remission of disease was achieved in 56% of patients; 78% for patients with microadenoma and 47% for patients with macroadenomas, respectively. No cases of mortality or major immediate postoperative complications were observed. Tumour size, high hormone levels and dural invasion were significantly correlated to a poor surgical outcome. The recurrence rates ranged between 0 and 24%, being higher for PRL-secreting tumours. In conclusion, TSS is safe and effective in secreting pituitary tumours. It is still the first treatment for GH- and ACTH-secreting adenomas, whereas in patients with prolactinomas, surgery should be reserved for cases of resistance or intolerance to dopamine agonists.
| Original language | English |
|---|---|
| Pages (from-to) | 251-256 |
| Number of pages | 6 |
| Journal | Neurological Sciences |
| Volume | 25 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Dec 2004 |
Fingerprint
Keywords
- Acromegaly
- Cushing's disease
- Pituitary adenoma
- Prolactinoma
- Transsphenoidal surgery
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
Cite this
Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours : Outcome analysis in a series of 125 patients. / Esposito, V.; Santoro, A.; Minniti, Giuseppe; Salvati, M.; Innocenzi, G.; Lanzetta, G.; Cantore, G.
In: Neurological Sciences, Vol. 25, No. 5, 12.2004, p. 251-256.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours
T2 - Outcome analysis in a series of 125 patients
AU - Esposito, V.
AU - Santoro, A.
AU - Minniti, Giuseppe
AU - Salvati, M.
AU - Innocenzi, G.
AU - Lanzetta, G.
AU - Cantore, G.
PY - 2004/12
Y1 - 2004/12
N2 - Transsphenoidal surgery (TSS) is a well recognised treatment for secreting pituitary adenomas, however a very wide variation of clinical outcomes and recurrence rates has been reported, depending on the different criteria used to define the cure. We reported the clinical outcome of a large series of patients operated on for a secreting pituitary adenoma according to the most recent stringent criteria of biochemical remission nowadays accepted. One hundred and twenty-five consecutive patients with a secreting pituitary adenoma (42 PRL-, 67 GH- and 16 ACTH-secreting adenomas) who were operated on by the two same neurosurgeons were considered for the study. Biochemical remission of disease was achieved in 56% of patients; 78% for patients with microadenoma and 47% for patients with macroadenomas, respectively. No cases of mortality or major immediate postoperative complications were observed. Tumour size, high hormone levels and dural invasion were significantly correlated to a poor surgical outcome. The recurrence rates ranged between 0 and 24%, being higher for PRL-secreting tumours. In conclusion, TSS is safe and effective in secreting pituitary tumours. It is still the first treatment for GH- and ACTH-secreting adenomas, whereas in patients with prolactinomas, surgery should be reserved for cases of resistance or intolerance to dopamine agonists.
AB - Transsphenoidal surgery (TSS) is a well recognised treatment for secreting pituitary adenomas, however a very wide variation of clinical outcomes and recurrence rates has been reported, depending on the different criteria used to define the cure. We reported the clinical outcome of a large series of patients operated on for a secreting pituitary adenoma according to the most recent stringent criteria of biochemical remission nowadays accepted. One hundred and twenty-five consecutive patients with a secreting pituitary adenoma (42 PRL-, 67 GH- and 16 ACTH-secreting adenomas) who were operated on by the two same neurosurgeons were considered for the study. Biochemical remission of disease was achieved in 56% of patients; 78% for patients with microadenoma and 47% for patients with macroadenomas, respectively. No cases of mortality or major immediate postoperative complications were observed. Tumour size, high hormone levels and dural invasion were significantly correlated to a poor surgical outcome. The recurrence rates ranged between 0 and 24%, being higher for PRL-secreting tumours. In conclusion, TSS is safe and effective in secreting pituitary tumours. It is still the first treatment for GH- and ACTH-secreting adenomas, whereas in patients with prolactinomas, surgery should be reserved for cases of resistance or intolerance to dopamine agonists.
KW - Acromegaly
KW - Cushing's disease
KW - Pituitary adenoma
KW - Prolactinoma
KW - Transsphenoidal surgery
UR - http://www.scopus.com/inward/record.url?scp=11244257350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11244257350&partnerID=8YFLogxK
U2 - 10.1007/s10072-004-0351-z
DO - 10.1007/s10072-004-0351-z
M3 - Article
C2 - 15624082
AN - SCOPUS:11244257350
VL - 25
SP - 251
EP - 256
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - 5
ER -